Patents by Inventor Federico MENSA
Federico MENSA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082245Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 3, 2023Publication date: March 14, 2024Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan NG, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Patent number: 11639390Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.Type: GrantFiled: July 16, 2021Date of Patent: May 2, 2023Assignee: AbbVie Inc.Inventors: Jing Min, Teresa (Iok-Chan) Ng, Lorenzo Benatuil, Jacqueline Bixby, Tatyana Dekhtyar, Feng Dong, Axel Hernandez, Jr., Preethi Krishnan, Liangjun Lu, Federico Mensa, Renee Miller, Gautam Sahu
-
Publication number: 20220017624Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.Type: ApplicationFiled: July 16, 2021Publication date: January 20, 2022Inventors: Jing Min, Teresa (Iok-Chan) Ng, Lorenzo Benatuil, Jacqueline Bixby, Tatyana Dekhtyar, Feng Dong, Axel Hernandez, Jr., Preethi Krishnan, Liangjun Lu, Federico Mensa, Renee Miller, Gautam Sahu
-
Publication number: 20200368229Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 2, 2017Publication date: November 26, 2020Applicant: AbbVie Inc.Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20200222397Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 20, 2018Publication date: July 16, 2020Applicant: AbbVie Inc.Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20170360783Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 1, 2017Publication date: December 21, 2017Applicant: AbbVie Inc.Inventors: Christine Collins, Emily O. Dumas, Bo Fu, Abhishek Gulati, Yiran Bonnie Hu, Jens Kort, Matthew Kosloski, Preethi Krishnan, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Susan Rhee, Nancy S. Shulman, Roger Trinh, Rolado M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20170333428Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 2, 2017Publication date: November 23, 2017Applicant: AbbVie Inc.Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Rogert Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20130288957Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that has genetic variations located near the IL28B gene, including SNP rs12979860 with a CC or non-CC genotype and SNP rs8099917 with a TT or non-TT genotype.Type: ApplicationFiled: March 13, 2013Publication date: October 31, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Federico MENSA, Gerhard NEHMIZ
-
Publication number: 20130261050Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient having compensated liver disease.Type: ApplicationFiled: March 14, 2013Publication date: October 3, 2013Applicant: Boehringer Ingelheim International GmbHInventor: Federico MENSA